4 Yield Traps Paying Over 6% That Retirees Should Watch Out For

Published November 20, 2026, 9:15am ET · 5 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

An overlay with '10.2% ARCC YIELD' in large white and gold text on a dark green gradient covers the left side of the image. To the right, a smiling senior man with grey hair, wearing a red and brown plaid shirt and blue jeans, is seen placing a tan envelope into a dark green metal mailbox. The setting is an autumnal suburban neighborhood with colorful fall leaves scattered on the green grass and sidewalk. Trees with red, orange, and yellow foliage line the street under a clear blue sky, and a house is partially visible in the background.
A prominent 10.2% ARCC yield is displayed, representing the type of attractive returns retirees might seek. The article, however, explores the potential pitfalls of such high yields, classifying them as possible 'yield traps'. © 24/7 Wall St.

A double-digit yield can look like a steady paycheck, but it is only as reliable as the cash behind it. AGNC Investment (NASDAQ:AGNC) shows the risk. Its tangible net book value per share fell 16.9% to $7.13[1] in a single quarter, and it kept sending out monthly checks the whole time. When a payout runs ahead of its earnings base, a retiree can end up with a smaller check and a lower share price at once.

Quick test: a dividend holds up when the right earnings measure for that type of business covers it, free cash flow pays for it, and the company isn’t adding debt or issuing new shares to keep it going.

AGNC Investment (AGNC): An 18% Yield on Shrinking Book Value

AGNC pays $0.12 per share monthly, or $1.44 annualized, for a yield of about 18.2%. Much of that yield comes from a falling share price. The stock is at $7.90, down 17.28% year to date and 8.98% in the past month.

For a mortgage REIT, the right test is net spread income measured against the dividend, along with the direction of book value. In the third quarter, net spread and dollar roll income was $0.37 per share[2] against $0.36 in dividends, a cushion of one cent. That income declined $0.03[2] from the second quarter. The net interest spread narrowed to 1.86% from 2.00%[1]. Leverage rose to 7.9 times[2] tangible equity from 7.4 times. The economic return was -12.7%[2]. AGNC also sold 97.6M shares for $992M[1] through its at-the-market program. The company has cut before. It lowered the monthly payout from $0.16 to $0.12 in March 2020, and earlier payouts ran as high as $0.22.

The CEO said "our dividend continues to be well-aligned with the economics of our business,"[2] citing a 97% hedge ratio and new investments earning about 19%. For the payout to hold, rate volatility has to ease and the spread has to stop shrinking.

Ares Capital (ARCC): Earnings Have Fallen Below the Dividend

Ares Capital (NASDAQ:ARCC | ARCC Price Prediction) pays $0.48 quarterly, which works out to a 10.2% yield. It has paid stable or higher regular dividends for 69 consecutive quarters[3]. The payout itself drives this yield, since the share price has risen. Shares are up 5.69% over the past year.

For a business development company (BDC), the right test is net investment income per share against the distribution. Core EPS was $0.46[4] in the third quarter and $0.47 in the second, so earnings fell short of the $0.48 dividend in both quarters. Loans not paying interest rose to 2.4% of investments at cost from 1.8% at year-end 2025. Net asset value per share slipped to $19.31 from $19.94[4]. The quarter brought $52M in net realized losses[4], compared with $162M in gains a year earlier. Borrowing is also getting more expensive: new 6.250% notes replaced maturing 2.150% notes.

Ares Capital has a buffer. It carries $1.37 per share[3] of undistributed taxable income from prior years (spillover income) and a $2.5 billion investment backlog, and it expects the MidCap Financial deal to be "modestly accretive" to earnings. If core earnings stay below the dividend, though, that spillover will shrink.

Verizon (VZ): Strong Coverage, Heavy Debt

Verizon (NYSE:VZ) yields 6.12% on a $0.7075 quarterly payout, which it raised from $0.69 in April. Shares are up 21.14% year to date. Verizon carries the least risk on this list.

Earnings and cash flow cover the dividend. Full-year adjusted EPS guidance is $5.04 to $5.06[5], and third-quarter free cash flow reached $7.80B. The concern is the balance sheet. Verizon has $166.2B[5] of debt, and interest expense rose 17.2% year over year. Net unsecured debt reached 2.5x adjusted EBITDA in the second quarter before easing to 2.3x[6]. Revenue grew only 1.4%[5], and postpaid wireless revenue per account fell 1.9%. Over nine months, Verizon spent $8.8 billion[6] on dividends and $4 billion on buybacks, money that could otherwise have paid down debt.

To keep its dividend growing, Verizon needs to hit its leverage target in 2027[6] and deliver the free cash flow growth it guided to, approaching 12%[5].

Pfizer (PFE): Patent Expirations Behind a 6% Yield

Pfizer (NYSE:PFE) pays $1.72 annualized, a yield of about 6.22%. Shares remain 28.36% below their level of five years ago. Pfizer has cut before: the quarterly dividend went from $0.32 to $0.16 in 2009.

Adjusted EPS guidance of $2.95 to $3.05 covers the payout. On a GAAP basis, trailing diluted EPS is $0.70, pulled down partly by a $3.8B write-down of a failed drug candidate. The free cash flow yield of 5.78% is below the dividend yield, which means free cash flow doesn’t fully cover the payout at today’s price. Pfizer paid $7.3 billion[7] in dividends through nine months, against $8.8 billion of operating cash flow. It plans no buybacks in 2026 and is focused on paying down debt.

Several key drugs are losing patent protection. U.S. sales of Ibrance and Xtandi face generic competition, and Eliquis loses exclusivity internationally at the end of 2026. Pfizer expects a $1.1B revenue hit from generics and biosimilars, and Paxlovid sales fell 63%. Recently launched and acquired products grew 32%, and Pfizer’s CFO says the company can "continue to invest and maintain the dividend"[7] through the patent expirations. Pfizer plans to issue 2027 guidance around mid-December[7], and that report is worth reading closely.

Retiree Checklist for Spotting a Yield Trap

  1. Check coverage with the right measure for the business: net spread income for mortgage REITs, net investment income for BDCs, and EPS plus free cash flow for ordinary companies.
  2. Check whether a falling share price is what pushed the yield up.
  3. Look for rising leverage, new share sales, or shrinking book value.
  4. Review the dividend history for past cuts.

When a dividend gets cut, the share price usually falls too, so the income loss and the price loss tend to arrive together. Check the coverage before relying on the yield (we laid out the seven warning signs that a big yield is about to be cut in a free dividend traps report worth keeping handy).

Contact [email protected] for any questions or corrections.

Lee Jackson

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad, diverse career, including a stint as creative services director at an NBC affiliate in Austin, Texas, gives him unique insight into the financial industry.

Lee Jackson's journey in the financial industry spans more than 30 years, including nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career spanned pivotal sell-side Wall Street events, from the dot-com rise and bubble to the Long-Term Capital Management debacle, 9/11, and the Great Recession of 2008. This reflects his resilience and adaptability amid market volatility.

Lee Jackson’s practical financial industry experience, gained through a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing across various platforms. This unique combination allows him to shed light on the intricacies of Wall Street in a way only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

All articles →

Sources

  1. AGNC Investment Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  2. AGNC Investment Corp. Q3 2026 earnings callAGNC Investment Corp.
  3. Ares Capital Corporation Q3 2026 earnings callAres Capital Corporation
  4. Ares Capital Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  5. Verizon Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  6. Verizon Communications Inc. Q3 2026 earnings callVerizon Communications Inc.
  7. Pfizer, Inc. Q3 2026 earnings callPfizer, Inc.